Balance Sheet Components |
4.Balance Sheet Components
Cash Equivalents and Short-term Investments
The fair values of cash equivalents and short-term investments classified as available-for-sale securities, consisted of the following (in thousands):
|
June 30, 2015 |
|
|
|
|
|
|
Gross Unrealized |
|
|
|
|
|
|
Amortized
Cost |
|
|
Gains |
|
|
Losses |
|
|
Estimated
Fair Value |
|
Money market funds classified as cash equivalents |
$ |
26,090 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
26,090 |
|
Corporate bonds classified as cash equivalents |
|
8,045 |
|
|
|
— |
|
|
|
(2 |
) |
|
|
8,043 |
|
Commercial paper classified as short-term investments |
|
4,394 |
|
|
|
— |
|
|
|
— |
|
|
|
4,394 |
|
Corporate bonds classified as short-term investments |
|
216,249 |
|
|
|
16 |
|
|
|
(204 |
) |
|
|
216,061 |
|
Asset backed securities classified as short-term investments |
|
23,057 |
|
|
|
1 |
|
|
|
(19 |
) |
|
|
23,039 |
|
U.S. Government agency securities classified as short-term
investments |
|
30,185 |
|
|
|
2 |
|
|
|
(3 |
) |
|
|
30,184 |
|
Total |
$ |
308,020 |
|
|
$ |
19 |
|
|
$ |
(228 |
) |
|
$ |
307,811 |
|
|
December 31, 2014 |
|
|
|
|
|
|
Gross Unrealized |
|
|
|
|
|
|
Amortized
Cost |
|
|
Gains |
|
|
Losses |
|
|
Estimated
Fair Value |
|
Money market funds classified as cash equivalents |
$ |
8,627 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
8,627 |
|
Corporate bonds classified as cash equivalents |
|
3,806 |
|
|
|
1 |
|
|
|
— |
|
|
|
3,807 |
|
Corporate bonds classified as short-term investments |
|
149,303 |
|
|
|
4 |
|
|
|
(172 |
) |
|
|
149,135 |
|
Asset backed securities classified as short-term investments |
|
9,546 |
|
|
|
— |
|
|
|
(4 |
) |
|
|
9,542 |
|
U.S. Government agency securities classified as short-term
investments |
|
4,488 |
|
|
|
1 |
|
|
|
(4 |
) |
|
|
4,485 |
|
Other classified as cash equivalents |
|
209 |
|
|
|
— |
|
|
|
— |
|
|
|
209 |
|
Total |
$ |
175,979 |
|
|
$ |
6 |
|
|
$ |
(180 |
) |
|
$ |
175,805 |
|
At June 30, 2015, the remaining contractual maturities of available-for-sale securities were less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented.
Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
|
|
June 30, |
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
Research and clinical study expenses |
|
$ |
5,714 |
|
|
$ |
2,703 |
|
Payroll and related expenses |
|
|
4,972 |
|
|
|
4,205 |
|
Other |
|
|
2,030 |
|
|
|
667 |
|
Total accrued liabilities |
|
$ |
12,716 |
|
|
$ |
7,575 |
|
|